Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:51:49.433Z.
Consensus retrieved: 2026-10-06T12:44:17.436Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:51:49.433Z.
Quote observation: 2026-10-06T15:50:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 88e906b5462319013e69f4ee379284aaffb96e00f9acc248208650345dd3e90c
Forward PE Ratio (N/A) = Dated Quote Price ($32.37) / Consensus Forward EPS ($-2.94)
FORWARD PE RATIO
N/A
Immunovant, Inc.
Market Cap
$6.68B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Immunovant, Inc. (IMVT) | $6.68B | N/A |
| Chemed Corporation (CHE)vs › | $6.67B | 20.03 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.59B | N/A |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.56B | 20.06 |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 18.47 |
| Alkermes plc (ALKS)vs › | $7.14B | N/A |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.39B | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $6.02B | 32.29 |
| GRAIL Inc. (GRAL)vs › | $6.00B | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.95B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-03-31
At the dated quote price of $32.37, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-03-31 | $-2.94 | $-3.13 – $-2.63 | 9 | n/m |
| 2028-03-31 | $-2.92 | $-3.37 – $-2.51 | 8 | n/m |
| 2029-03-31 | $-1.87 | $-3.40 – $-0.04 | 11 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
